Jimin Health released its 2026 interim report. During the reporting period, the company's total operating revenue was 338 million yuan, down 7.86 percent year on year, and net profit attributable to the parent company was a loss of 49.423 million yuan. Net cash inflow from operating activities was 12.5691 million yuan, the asset-liability ratio was 46.93 percent, gross margin was 36.32 percent, return on equity was negative 4.54 percent, and diluted earnings per share was negative 0.10 yuan. The company had 33,800 shareholders, and the top ten shareholders held 45.59 percent of the shares.
Zhejiang Chimin Pharm Co LtdCompany reported net loss of 49.423 million yuan in interim results.